New England Biolabs® releases Rapid PNGase F for biotherapeutic development and production

Next-generation glycosidase enables complete protein deglycosylation in minutes

Ipswich, MA (January 27, 2015) – New England Biolabs (NEB®) today announced the release of its new Rapid PNGase F glycosidase at the 2015 WCBP Meeting in Washington, DC. This broad-specificity glycosidase completely removes N-glycans from antibodies and fusion proteins in 10 minutes or less. This important technical advancement offers the potential to accelerate the quality control analysis of antibody-based therapeutics.

PNGase F is a broad specificity amidase that liberates high mannose, hybrid and complex N-linked glycans from glycoproteins. It performs a critical first step in workflows that permit the structural analysis of released N-glycans. Current PNGase F products on the market require long incubation times ranging from one hour to overnight, and often still result in incomplete N-glycan removal. NEB’s new Rapid PNGase F addresses these limitations.

Rapid PNGase F expands NEB’s portfolio of reagents that can be used to enhance biopharma product development and production. Antibodies and antibody fusion proteins are becoming more widely used as therapeutic agents, and accurate analysis of an antibody’s N-glycans is a critical factor in designing an efficacious drug. Rapid PNGase F accelerates this analysis.

“Monitoring of antibody glycosylation during development and production requires complete and accurate N-glycan profiling, preferably in the shortest time possible. Rapid PNGase F allows complete deglycosylation of therapeutic monoclonal antibodies in just minutes, and is compatible with LC-MS applications,” said Chris Taron, Scientific Director of Protein Expression and Modification Research at NEB.

Central to NEB’s product development strategy is collaboration with third parties that develop innovative analysis and separation instrument technologies for biopharma drug development. One such collaboration with Waters Corporation has contributed to the release of their latest innovative glycobiology product.

“Our collaboration with New England Biolabs and their Rapid PNGase F deglycosylation technology played a pivotal role in our ability to create the new GlycoWorks RapiFluor-MS™ N-Glycan Kit, a set of products that enable a revolutionary, streamlined N-glycan sample preparation workflow.” shared Jennifer Fournier, Product Marketing Manager, and Matthew Lauber, Ph.D., Senior Applications Chemist at Waters Corporation.

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit

NEW ENGLAND BIOLABS® and NEB® are registered trademarks of New England Biolabs, Inc.

RAPIFLUOR-MS™ is a trademark of Waters Corporation, Inc.

Contact information:
Deana D. Martin, Ph.D.
Marketing Communications Manager
New England Biolabs
240 County Road
Ipswich, MA 01938
Tel: 978-380-7464


Return to News Listing